Effectiveness of Atypical Versus Conventional Antipsychotics in Treating Schizophrenia

This study has been completed.

Sponsors and Collaborators:	National Institute of Mental Health (NIMH) Yale University
Information provided by:	National Institute of Mental Health (NIMH)
ClinicalTrials.gov Identifier:	NCT00237861

Purpose

This study will compare the effectiveness of newer atypical antipsychotics versus older conventional antipsychotics in treating schizophrenia.

Condition	Intervention	Phase
Schizophrenia	Drug: risperidone Drug: olanzapine Drug: quetiapine	Phase IV

MedlinePlus related topics: Schizophrenia

Drug Information available for: Risperidone Quetiapine Quetiapine fumarate Olanzapine

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Single Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	Effectiveness of Atypical Vs Conventional Antipsychotics

Further study details as provided by National Institute of Mental Health (NIMH):

Primary Outcome Measures:

PANSS
Retention.

Secondary Outcome Measures:

EPS, TD.

Detailed Description:

At seven participating hospitals, acutely exacerbated patients with schizophrenia were randomly assigned to treatment with antipsychotic from the atypical class vs antipsychotic from the conventional class. Medication choice within class, dose, concomitant medications, and other prescribing decisions were left to the community prescriber. Patients were followed for one year after discharge.

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

hospitalized for schizophrenia

Exclusion Criteria:

none

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00237861

Sponsors and Collaborators

National Institute of Mental Health (NIMH)

Yale University

Investigators

Principal Investigator:

Scott W Woods, MD

Yale University

More Information

Study ID Numbers:	MH57292
Study First Received:	October 7, 2005
Last Updated:	February 22, 2006
ClinicalTrials.gov Identifier:	NCT00237861
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Schizophrenia
Quetiapine
Dopamine
Mental Disorders
Risperidone

Olanzapine
Psychotic Disorders
Serotonin
Schizophrenia and Disorders with Psychotic Features

Additional relevant MeSH terms:

Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Tranquilizing Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Gastrointestinal Agents
Psychotropic Drugs
Antiemetics
Central Nervous System Depressants
Dopamine Antagonists

Antipsychotic Agents
Serotonin Uptake Inhibitors
Pharmacologic Actions
Serotonin Antagonists
Serotonin Agents
Autonomic Agents
Therapeutic Uses
Dopamine Agents
Peripheral Nervous System Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on January 16, 2009